{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:56:58Z","timestamp":1777895818435,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.trsl.2026.02.010","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T17:19:11Z","timestamp":1772126351000},"page":"1-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Routine detection of reactive Cyfra21-1-specific CD8+ T cells and its predictive value for responsiveness to PD-1\/PD-L1 inhibitor therapy in NSCLC patients"],"prefix":"10.1016","volume":"290","author":[{"given":"Shilong","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yandan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyue","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangping","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3748-3742","authenticated-orcid":false,"given":"Chuanlai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.trsl.2026.02.010_bib0001","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41571-023-00838-y","article-title":"From ESMO 2023: advances in lung cancer","volume":"21","author":"Sidaway","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.trsl.2026.02.010_bib0002","article-title":"Immunotherapy resistance in non-small-cell lung cancer: from mechanism to clinical strategies","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"issue":"16","key":"10.1016\/j.trsl.2026.02.010_bib0003","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1158\/1078-0432.CCR-16-2821","article-title":"Phase I trial of intratumoral injection of CCL21 gene-modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8(+) T-cell infiltration","volume":"23","author":"Lee","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.trsl.2026.02.010_bib0004","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.imlet.2020.01.001","article-title":"Detection of tumor antigens and tumor-antigen specific T cells in NSCLC patients: correlation of the quality of T cell responses with NSCLC subtype","volume":"219","author":"Palata","year":"2020","journal-title":"Immunol Lett"},{"issue":"1","key":"10.1016\/j.trsl.2026.02.010_bib0005","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40425-017-0274-x","article-title":"Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC","volume":"5","author":"Tosch","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.trsl.2026.02.010_bib0006","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/1758834016678375","article-title":"Predictive biomarkers and effectiveness of MUC1-targeted dendritic-cell-based vaccine in patients with refractory non-small cell lung cancer","volume":"9","author":"Teramoto","year":"2017","journal-title":"Ther Adv Med Oncol"},{"issue":"7","key":"10.1016\/j.trsl.2026.02.010_bib0007","doi-asserted-by":"crossref","DOI":"10.4161\/onci.25205","article-title":"SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer","volume":"2","author":"Dhodapkar","year":"2013","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.trsl.2026.02.010_bib0008","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00262-017-1978-y","article-title":"TANTIGEN: a comprehensive database of tumor T cell antigens","volume":"66","author":"Olsen","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"10.1016\/j.trsl.2026.02.010_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2021.06.013","article-title":"Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma","volume":"54","author":"Cheng","year":"2021","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.trsl.2026.02.010_bib0010","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.21037\/tcr-21-527","article-title":"The value of combined detection of CEA, CYFRA21-1, SCC-Ag, and pro-GRP in the differential diagnosis of lung cancer","volume":"10","author":"Li","year":"2021","journal-title":"Transl Cancer Res"},{"issue":"4","key":"10.1016\/j.trsl.2026.02.010_bib0011","first-page":"317","article-title":"The prognostic value of cytokeratin 19 expression in non-small cell lung cancer","volume":"75","author":"Kosacka","year":"2007","journal-title":"Pneumonol Alergol Pol"},{"issue":"1","key":"10.1016\/j.trsl.2026.02.010_bib0012","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.trsl.2026.02.010_bib0013","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannov\u00e1","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.trsl.2026.02.010_bib0014","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.trsl.2026.02.010_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.847105","article-title":"Screening and identification of HBV epitopes restricted by multiple prevalent HLA-A allotypes","volume":"13","author":"Ding","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2026.02.010_bib0016","article-title":"Predominant T-cell epitopes of SARS-CoV-2 restricted by multiple prevalent HLA-B and HLA-C allotypes in Northeast Asia","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.trsl.2026.02.010_bib0017","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1038\/s41423-021-00784-8","article-title":"Screening HLA-A-restricted T cell epitopes of SARS-CoV-2 and the induction of CD8(+) T cell responses in HLA-A transgenic mice","volume":"18","author":"Jin","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.trsl.2026.02.010_bib0018","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.trsl.2026.02.010_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113404","article-title":"Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: impact of clinicopathological factors and indirect comparison between treatment strategies","volume":"195","author":"Nuccio","year":"2023","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.trsl.2026.02.010_bib0020","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1007\/s00262-023-03441-3","article-title":"The landscape of objective response rate of anti-PD-1\/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating","volume":"72","author":"Mao","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.trsl.2026.02.010_bib0021","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.annonc.2023.10.125","article-title":"Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review","volume":"35","author":"Prelaj","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.trsl.2026.02.010_bib0022","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s12957-023-03215-2","article-title":"Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis","volume":"21","author":"Cui","year":"2023","journal-title":"World J Surg Oncol"},{"issue":"7","key":"10.1016\/j.trsl.2026.02.010_bib0023","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1001\/jamaoncol.2020.1046","article-title":"Outcomes following immune checkpoint inhibitor treatment of patients with microsatellite instability-high cancers: a systematic review and meta-analysis","volume":"6","author":"Petrelli","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.trsl.2026.02.010_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101134","article-title":"The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: a systematic review and meta-analysis","volume":"41","author":"Li","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"8","key":"10.1016\/j.trsl.2026.02.010_bib0025","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.3390\/cancers13081922","article-title":"Anti-PD-1\/PD-L1 based combination immunotherapy to boost antigen-specific CD8(+) T cell response in hepatocellular carcinoma","volume":"13","author":"Pe\u00f1a-Asensio","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.trsl.2026.02.010_bib0026","article-title":"Tumor-infiltrating PD-1(hi)CD8(+)-T-cell signature as an effective biomarker for immune checkpoint inhibitor therapy response across multiple cancers","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.trsl.2026.02.010_bib0027","first-page":"886","article-title":"Diagnostic value of serum tumor markers CEA, CYFRA21-1, SCCAg, NSE and ProGRP for lung cancers of different pathological types","volume":"42","author":"Gao","year":"2022","journal-title":"Nan Fang Yi Ke Xue Xue Bao"},{"key":"10.1016\/j.trsl.2026.02.010_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102606","article-title":"Shaping the tumor immune microenvironment of SCLC: mechanisms, and opportunities for immunotherapy","volume":"120","author":"Chen","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.trsl.2026.02.010_bib0029","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/cam4.493","article-title":"Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer","volume":"4","author":"Zhang","year":"2015","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.trsl.2026.02.010_bib0030","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1186\/s12885-022-09728-5","article-title":"Development and validation of reassigned CEA, CYFRA21-1 and NSE-based models for lung cancer diagnosis and prognosis prediction","volume":"22","author":"Yuan","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.trsl.2026.02.010_bib0031","first-page":"1","article-title":"Predictive value of serum SCCA and CYFRA21-1 levels on radiotherapy efficacy and prognosis in patients with non-small cell lung cancer","author":"Chen","year":"2023","journal-title":"Biotechnol Genet Eng Rev"},{"key":"10.1016\/j.trsl.2026.02.010_bib0032","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-61779-325-7_1","article-title":"Unique strengths of ELISPOT for T cell diagnostics","volume":"792","author":"Lehmann","year":"2012","journal-title":"Methods Mol Biol"},{"issue":"12","key":"10.1016\/j.trsl.2026.02.010_bib0033","article-title":"Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent","volume":"12","author":"Zhu","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.trsl.2026.02.010_bib0034","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annonc.2023.07.006","article-title":"Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1","volume":"34","author":"Besse","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.trsl.2026.02.010_bib0035","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S1470-2045(16)00099-1","article-title":"Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Vansteenkiste","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.trsl.2026.02.010_bib0036","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1081\/PB-200054732","article-title":"Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions","volume":"35","author":"Murphy","year":"2005","journal-title":"Prep Biochem Biotechnol"},{"issue":"5","key":"10.1016\/j.trsl.2026.02.010_bib0037","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1158\/1535-7163.MCT-10-1050","article-title":"Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells","volume":"10","author":"Raina","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.trsl.2026.02.010_bib0038","doi-asserted-by":"crossref","first-page":"110","DOI":"10.36468\/pharmaceutical-sciences.spl.221","article-title":"Expression and clinical significance of tumor markers CEA and CYFRA21-1 in patients with lung cancer","volume":"83","author":"Zhang","year":"2021","journal-title":"Indian J Pharm Sci"},{"issue":"s1","key":"10.1016\/j.trsl.2026.02.010_bib0039","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.3233\/TUB-220042","article-title":"CYFRA 21-1, CA 125 and CEA provide additional prognostic value in NSCLC patients with stable disease at first CT scan","volume":"46","author":"Muley","year":"2024","journal-title":"Tumour Biol"},{"issue":"s1","key":"10.1016\/j.trsl.2026.02.010_bib0040","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.3233\/TUB-230001","article-title":"Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150","volume":"46","author":"Mang","year":"2024","journal-title":"Tumour Biol"},{"issue":"34","key":"10.1016\/j.trsl.2026.02.010_bib0041","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1111\/1759-7714.15126","article-title":"Recent advances in neoantigen vaccines for treating non-small cell lung cancer","volume":"14","author":"Su","year":"2023","journal-title":"Thorac Cancer"},{"issue":"19","key":"10.1016\/j.trsl.2026.02.010_bib0042","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"10183","key":"10.1016\/j.trsl.2026.02.010_bib0043","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.trsl.2026.02.010_bib0044","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524426000484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524426000484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:05:13Z","timestamp":1777622713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524426000484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":44,"alternative-id":["S1931524426000484"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2026.02.010","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Routine detection of reactive Cyfra21-1-specific CD8+ T cells and its predictive value for responsiveness to PD-1\/PD-L1 inhibitor therapy in NSCLC patients","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2026.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}